{"id":"NCT02074514","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection","officialTitle":"A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2015-09","completion":"2015-11","firstPosted":"2014-02-28","resultsPosted":"2016-10-25","lastUpdate":"2016-10-25"},"enrollment":117,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic HCV Infection"],"interventions":[{"type":"DRUG","name":"Sofosbuvir","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"type":"DRUG","name":"RBV","otherNames":[]}],"arms":[{"label":"Sofosbuvir+RBV 16 weeks","type":"EXPERIMENTAL"},{"label":"Sofosbuvir+RBV 24 weeks","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + ribavirin (RBV) in treatment-naive adults with chronic genotype 1 or 3 hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF + RBV 16 Weeks GT1","deltaMin":90,"sd":null},{"arm":"SOF + RBV 24 Weeks GT1","deltaMin":96.4,"sd":null},{"arm":"SOF + RBV 16 Weeks GT3","deltaMin":100,"sd":null},{"arm":"SOF + RBV 24 Weeks GT3","deltaMin":93.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":13,"countries":["India"]},"refs":{"pmids":["27933698"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":59},"commonTop":["Asthenia","Headache","Cough","Fatigue","Pain"]}}